Patent intelligence · US
US 7619112
Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
Patent details — US 7619112
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 17, 2009
- Expiration
- Nov 12, 2029
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Claims
- 4
- CPC classes
- A61P, A61P25/08
Quick answer
US 7619112 (Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Nov 17, 2009. Expires Nov 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61P, A61P25/08
More from TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 7619112?
US 7619112 (Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Nov 17, 2009. Expires Nov 12, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7619112?
TEVA PHARMACEUTICAL INDUSTRIES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 7619112 expire?
Our index shows an expiration date of Nov 12, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.